GSK 3915393
Alternative Names: GSK-3915393Latest Information Update: 06 Sep 2024
At a glance
- Originator GlaxoSmithKline
- Developer GlaxoSmithKline; GSK
- Class Antifibrotics; Digestion aids
- Mechanism of Action Transglutaminase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Idiopathic pulmonary fibrosis
- Phase I Pulmonary fibrosis
- Research Unspecified
- Discontinued Coeliac disease
Most Recent Events
- 19 Mar 2024 GlaxoSmithKline plans a phase II TRANSFORM trial in Idiopathic pulmonary fibrosis (Unspecified) in April 2024
- 08 Nov 2023 Phase-I clinical trials in Pulmonary fibrosis (unspecified route) (GSK pipeline, November 2023)
- 02 Feb 2023 Discontinued - Phase-I for Coeliac disease in United Kingdom (IV) as of February 2023 (GlaxoSmithKline pipeline, February 2023)